The Clem Jones Centre for Regenerative Medicine was established in 2011 by a grant from the Clem Jones Foundation to develop a stem cell therapy for age-related macular degeneration (AMD). AMD is a disease of ageing characterised by the loss of retinal pigment epithelial (RPE) cells at the back of the eye which support the photoreceptors which detect light. In AMD, the loss of RPE cells leads to photoreceptor death and permanent blindness. There is no cure for this disease, and available treatments give only transient relief. The transplantation of RPE cells derived in culture from pluripotent stem cells aims to halt or reverse vision loss by preventing photoreceptor death. It remains one of the most promising applications of stem cell technology. A decade on, and researchers at Bond have developed procedures for generating retinal cells from stem cells which are world-leading and under patent protection. The path ahead to translate this work into a clinical therapy is complex and expensive. The Clem Jones Foundation continues to partially fund our research, but government grants and donations from the public are needed to advance the mission. You can assist on the pathway to clinical application of this work by making a tax-deductible donation to the Centre. All funds received will be directed into research on bringing a stem cell therapy for AMD to the clinic.